Daxor Corporation
DXRHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframeDaxor Corporation engages in medical instrumentation and biotechnology operations. At a $54.0M market cap, Daxor Corporation ranks as a micro-cap company within healthcare. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Market Cap
$54.0M
Beta
0.35
P/E (TTM)
8.56
P/E (Fwd)
—
EPS (TTM)
$1.08
EPS (Fwd)
—
ROE
14.2%
ROA
-2.6%
Cash
—
Total Debt
$0
Free CF
$333,869
52W Change
-32.9%
Annual Financials
Cash vs Debt
Where DXR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DXR finished 5.29% below its 150-day moving average ($10.39) and 9.97% below its 200-day moving average ($10.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DXR overbought or oversold?
At the October 20, 2026 close, DXR's RSI(14) was 14.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Daxor Corporation carries $0 in total debt, a figure that investors should evaluate relative to the company's earnings power. The company generates $334K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 14.2%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $5.8M (2021) to $10.3M (2025), reflecting a 77% increase over the period.
With a beta below 0.7, Daxor Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Daxor Corporation's trajectory.